(NASDAQ:QNRX) Shares are up more than 39% in pre market trading. Currently at $.86 cents on the Nasdaq. More than 1500 shares have traded hands.

Skinvisible, Inc.  is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. (“Quoin”) (NASDAQ:QNRX), has received U.S. FDA acceptance of its Investigational New Drug (IND) application for its licensed formulation which uses Skinvisible’s Invisicare® proprietary drug delivery technology. The topical formulation “QRX003” was developed to treat Nethertons Syndrome, a debilitating hereditary disorder that affects the skin, hair and the immune system. There currently is no cure or approved treatment for Netherton Syndrome.

https://www.digitaljournal.com/pr/skinvisible-announces-first-invisicare-delivery-technology-product-to-receive-u-s-fda-acceptance-of-investigational-new-drug